Barron's : Italy’s Market Likes the New Prime Minister. She’s Showing Her Modera

Italy’s Market Likes the New Prime Minister. She’s Showing Her Moderate Side.

Giorgia Meloni wasn’t elected to comfort the afflicted.

The Italian prime minister, who swapped her trademark white suit for jeans this past week to wade through flooded villages in the Emilia-Romagna region, swept to power last autumn on a right-populist platform of containing immigration, slashing taxes, and sticking it to the overbearing eurocrats in Brussels.

She hasn’t done much on any of these fronts. “So far, Meloni has been much ado about nothing,” says Kaspar Hense, a senior portfolio manager in fixed income at RBC BlueBay Asset Management.

That’s a good thing, from markets’ point of view. The yield spread of Italian 10-year bonds over German bunds, a key metric of investor confidence, has tightened by 45 basis points since Meloni’s Sept. 26 election, to below 200.

Standard & Poor’s and Moody’s lately maintained Italy’s credit rating at the lowest investment-grade rung, rather than reduce it to junk.

The iShares MSCI Italy exchange-traded fund (ticker: EWI) has rallied with the rest of Europe, gaining 40%. No. 2 bank UniCredit (UCG.Italy) has led the surge, rising by two-thirds.

Candidate Meloni promised 260 billion euros ($280.4 billion) in tax cuts, Hense says. Her first budget delivered €10 billion. Firebrand Meloni once signed a manifesto declaring “no to Europe.”

In office, she has toed the European Union line on Russia, and held off on pledges to turn back migrants from Italy’s shores.

“At a European level, she has sought to position Italy as a constructive mainstream partner,” says Eoin Drea, senior researcher at the Wilfried Martens Centre for European studies.

That’s all bowing to reality. With national debt around 140% of gross domestic product, Italy can’t afford to sacrifice tax revenue in a supply-side experiment. Playing nice with Brussels is only sensible when the country is in line for up to €200 billion from a European Recovery Fund raised postpandemic. Italy’s suffering from Covid-19 makes it the top potential recipient.

The Recovery Fund cash, due to be doled out by 2026, could add 4% a year to Italy’s GDP after decades of anemic growth, Hense calculates. If only the country can figure out how to spend it.

Previous governments proposed nonessential projects like a new soccer stadium in Venice, sapping Brussels’ confidence, Drea says. Meloni has floated a build-back-better shift to green energy and transportation. Chances of a credible pipeline by a June 30 deadline still look slight.

Success in drawing down recovery funds could give Meloni a shot at bigger structural changes, says Matt Gertken, chief geopolitical strategist at BCA Research.

Voters like the breath of fresh air she brings as Italy’s first female prime minister, and one of its youngest, at 46. Her coalition holds some 60% of both houses of parliament, and trounced a divided opposition in regional elections around Rome and Milan in February.

So, her government might last longer than most of its 67 predecessors since World War II. EU largess could provide fiscal space for her tax cuts.

Her personal example might get more Italian women into the workforce, a structural shot in the arm. Female labor participation languishes at 40%, compared with 51% in France and 56% in Germany.

Not that Gertken is betting on it. “Basically, Italy is hoping to muddle through and avoid a direct clash with Brussels,” he says. Hense predicts that the bond rally has peaked, and he has turned “cautious” on Italian paper.

“Muddle through” isn’t the worst that was expected from Meloni’s first half year, though.

>>> US Research Calls

Research Calls

  • Upgrades:
    • Guardant Health (GH) upgraded to Buy from Neutral at Citigroup; tgt raised to $40
    • Hamilton Lane (HLNE) upgraded to Outperform from Perform at Oppenheimer; tgt $87
    • Materialise (MTLS) upgraded to Buy from Hold at Kepler; tgt $11
    • New Relic (NEWR) upgraded to Outperform from Sector Perform at RBC Capital Mkts; tgt raised to $95
    • Paramount Global (PARA) upgraded to Hold from Sell at Loop Capital; tgt $14
    • Pinnacle West (PNW) upgraded to Neutral from Underperform at BofA Securities; tgt raised to $78
    • Rio Tinto (RIO) upgraded to Overweight from Equal-Weight at Morgan Stanley
    • UWM Holdings (UWMC) upgraded to Buy from Hold at Jefferies; tgt raised to $7
  • Downgrades:
    • Annexon (ANNX) downgraded to Neutral from Buy at BofA Securities; tgt lowered to $3
    • Atlantica Yield (AY) downgraded to Sector Perform from Outperform at National Bank Financial; tgt $31
    • Linde plc (LIN) downgraded to Underperform from Outperform at Oddo BHF; tgt lowered to $339
    • MongoDB (MDB) downgraded to Sell from Neutral at Guggenheim; tgt raised to $210
    • Snowflake (SNOW) downgraded to Peer Perform from Outperform at Wolfe Research
    • Terran Orbital (LLAP) downgraded to Underperform from Buy at BofA Securities; tgt lowered to $1.35
  • Others:
    • American Public Education (APEI) initiated with a Hold at Truist; tgt $6
    • Banco Bilbao Vizcaya Argentaria (BBVA) initiated with an Equal Weight at Barclays
    • Clear Secure (YOU) resumed with a Hold at Stifel; tgt $28
    • CVS Health (CVS) initiated with an Overweight at Piper Sandler; tgt $85
    • Integer Holdings (ITGR) initiated with an Equal Weight at Wells Fargo; tgt $87
    • Madison Square Garden Entertainment (MSGE) initiated with a Neutral at Goldman; tgt $40
    • Madison Square Garden Entertainment (MSGE) initiated with an Equal-Weight at Morgan Stanley; tgt $40
    • Mirion Technologies (MIR) resumed with a Buy at Citigroup; tgt $11
    • OPAL Fuels (OPAL) initiated with a Buy at Janney; tgt $13
    • Physicians Realty Trust (DOC) initiated with a Mkt Outperform at JMP Securities; tgt $15.50
    • Strategic Education (STRA) initiated with a Hold at Truist; tgt $85
    • UnitedHealth (UNH) initiated with an Overweight at Piper Sandler; tgt $580
    • Vertex Pharma (VRTX) initiated with a Hold at WestPark Capital

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:

  • ULTA -8.9%, BIG -8.7%, HIBB -6%, DOMO -5.7%, RH -2.8%, DECK -2.7%, BKE -0.8%

Other news:

  • TLRY -19.1% (prices offering of $150 mln of 5.20% Convertible Senior Notes due 2027)
  • THRX -13.1% (reports data from ongoing Phase 1/2 trial of THE-630)
  • RLAY -3.8% (announces full dose escalation data for RLY-4008)
  • HMST -3.6% (to be removed from S&P Small Cap 600)
  • EXAS -1.6% (files mixed shelf securities offering)
  • SWTX -1.2% (announces presentation of additional data from Phase 3 DeFi Trial)
  • HLI -1.1% (reports certain revised financial info)

Analyst comments:

  • LLAP -1.6% (downgraded to Underperform from Buy at BofA Securities)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • MRVL +19%, PDD +15.1%, GPS +11.9%, WDAY +9.4% (also names new CFO), LGF.A +2.8%, BAH +2.4%, ARCE +1.7%, ADSK +1.2%

Other news:

  • PDSB +23.5% (announces interim data on PDS0101)
  • GNLX +6.5% (announces publication of topline data from Phase 2 VIRO-15 Trial)
  • PARA +5.6% (controlling shareholder secures $125 mln investment)
  • BOH +4.2% (to move to S&P SmallCap 600 from S&P MidCap 400)
  • GERN +3.8% (NDA submission on track for June 2023)
  • HCM +3.6% (Takeda Pharma and HUTCHMED receive NDA for Fruquintinib for treatment of previously treated metastatic colorectal cancer granted Priority Review; HCM also Highlights Presentations at the 2023 ASCO Annual Meeting)
  • IMAB +3% (announces phase 1b/2 study results of patients with advanced NSCLC)
  • SGML +3% (delivers on Zero Tailings strategy receives first payment and obtains premium pricing for sale of green lithium at 9% of LIOH Index)
  • GPCR +2% (initiates Phase 2a study of GSBR-1290)
  • CGEM +2% (to present first monotherapy clinical data for CLN-619)
  • CSTR +2% (completes $10 million common stock repurchase authorization and $20 million new authorization)
  • F +1.9% (reaches agreement with TSLA providing Ford EV customers access to Tesla Superchargers)
  • TEVA +1.5% (exploring options for bowel inflammation drug including a potential sale according to Bloomberg)
  • ZNTL +1.4% (Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting)
  • CUE +1.3% (presents data from phase 1 trials of CUE-101)

Analyst comments:

  • UWMC +4.1% (upgraded to Buy from Hold at Jefferies)
  • GH +3.9% (upgraded to Buy from Neutral at Citigroup)
  • NEWR +2.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)